When Do You Lose the Most Weight on Wegovy?

Why do the biggest losses happen mid-treatment, not at the start?

The first pen you inject contains 0.25 mg of semaglutide. That is a tolerability dose, its job is to let your body adjust to the medicine, not to drive significant fat loss. Side effects such as nausea are most likely in these early weeks, and appetite suppression at this stage is modest. Most people notice little change on the scales during the first month, which can feel discouraging.

As the dose steps up (through 0.5 mg, then 1.0 mg, then 1.7 mg, and finally to the 2.4 mg maintenance level) appetite suppression strengthens. Gastric emptying slows more meaningfully, the brain's hunger signals are dampened more consistently, and food intake tends to fall noticeably. This is when the steeper losses typically begin, and if you are wondering when you start to lose weight on Wegovy, it is often somewhere between months two and four. The rate then tends to be fastest in the middle phase of treatment, roughly months four to nine, before gradually slowing as the body reaches a new equilibrium.

This plateau is normal physiology, not failure. The body adapts its energy use over time, and the rate of loss slows even while the medicine continues working. Understanding that pattern (fast in the middle, slower later) helps people stay the course rather than abandoning treatment when the weekly numbers start to tick down. The general timeline of weight loss on Wegovy is worth reading alongside this page if you want the week-by-week picture.

What does the trial evidence actually show about the peak loss period?

The clearest data come from the STEP 1 trial, published in the New England Journal of Medicine, which followed 1,961 adults with obesity or overweight and at least one weight-related condition over 68 weeks. Average weight loss was approximately 15% of starting body weight on semaglutide 2.4 mg, compared with around 2.4% on placebo. Crucially, the loss curves show that participants were still losing weight at week 68, meaning the plateau had not fully set in for many people by the time the trial ended.

The 7.2 mg dose approved by the MHRA in early 2026 changes the picture somewhat. Trials at that higher dose reported average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide (Mounjaro) results. The maximum weight loss reported on Wegovy goes into more detail on what the top end of the evidence looks like.

One practical note: these are averages across large groups. People who start at a higher body weight tend to see larger absolute losses in kilograms, even when the percentage is similar. Age, sex, baseline metabolic rate and how consistently someone follows lifestyle guidance all shift where an individual lands relative to the trial average.

Does what you do during treatment affect when you lose the most?

Yes, and this is one of the things our prescribers at nume emphasise in aftercare. Wegovy reduces appetite; it does not remove the need for a reduced-calorie diet and regular activity. The trial participants followed structured lifestyle support alongside the medicine, which matters when interpreting the results.

Protein intake deserves particular attention. When weight loss is rapid, the body can lose lean muscle alongside fat. Keeping protein adequately represented in meals, especially during the months when loss is fastest, helps preserve muscle mass. Hydration is equally important: reduced food intake means less fluid from food, and some people on GLP-1 medicines underestimate how much water they need.

Timing and routine help too. Many people find it easiest to take their weekly injection on a fixed day, stored in the fridge door where it is visible, so it does not get missed. Consistent injection days mean consistent medicine levels, which supports consistent appetite suppression through the week. For practical guidance on getting the most from treatment, the page on maximising weight loss on Wegovy covers diet and activity specifics in detail.

It is also worth noting that starting a dose increase often brings a temporary return of stronger nausea, which can paradoxically suppress appetite even further in the short term. That is not sustainable weight loss (it is a side-effect response) and is one reason a prescriber monitors progress at each stage rather than simply stepping doses up automatically. You can read more about how semaglutide works if the mechanism interests you.

What happens to weight loss in the longer term, and what should you expect after stopping?

The honest answer is that Wegovy's effect on weight tends to wane once the medicine is stopped. Large trials following participants through discontinuation show that much of the weight lost is regained within a year of stopping, not because of any personal failing, but because the biological drivers of appetite and weight regulation reassert themselves. This is why NICE, in its guidance on semaglutide (TA875), recommends treatment within a specialist weight management service and notes the maximum recommended treatment duration of two years under NHS criteria. NICE's appraisal of semaglutide (Wegovy) sets out these recommendations in full.

For people continuing treatment beyond the initial rapid-loss phase, the goal shifts. Maintaining the new weight becomes the objective, and the medicine continues to assist with that even as the rate of further loss slows. Some people do continue to lose weight slowly beyond month twelve, particularly those who have not yet reached the highest tolerated dose.

Private treatment through a regulated service means no fixed two-year cap applies automatically, but every repeat order is reviewed clinically, that is how responsible prescribing works. If you want to understand what losing weight on Wegovy actually involves in practice, or if you are thinking about starting, the next step is a clinical assessment. Check your eligibility with our prescribers at nume's free consultation page.